

REMARKS

Claims 10 to 13 are pending and currently amended.

Claims 10 to 13 stand rejected under 102(b) as being anticipated by Mitra. As acknowledged by the Examiner, Mitra teaches compositions and methods for providing improved treatment, management, or mitigation of cold, cold-like, and/or flu-like symptoms comprising, *inter alia*, an expectorant, such as bromhexine or ambroxol.

The Applicant respectfully disagrees with the Examiner and submits that the present invention as claimed is not anticipated by Mitra.

Unlike Mitra, this application claims compositions and methods for inhibiting proliferation of influenza virus in a warm-blooded animal. The composition comprises ambroxol or a pharmaceutically acceptable salt thereof, bromhexin or a pharmaceutically acceptable salt thereof, or a combination of ambroxol or a pharmaceutically acceptable salt thereof and bromhexin or a pharmaceutically acceptable salt thereof.

The Applicant respectfully submits that the compositions and methods of the present invention as claimed are clearly distinguishable from the compositions and methods of Mitra. In particular, Mitra does not provide or even suggest compositions and methods for inhibiting proliferation of influenza virus in a warm-blooded animal. Therefore, the Applicant respectfully requests that the 102(b) rejection based on Mitra be reconsidered and withdrawn.

Respectfully submitted,
/THOMAS C. BLANKINSHIP/
Thomas C. Blankinship
Reg. No. 39,909